IsoPlexis Overview
- Year Founded
-
2013
- Status
-
Acquired/Merged
- Employees
-
290
- Latest Deal Type
-
Bankr. Admin/Reorg
- Investors
-
1
IsoPlexis General Information
Description
Developer of single-cell detection systems designed to identify patient immune responses at the single-cell level. The company offers single-cell detection systems, identifies immune responses, assesses safety and efficacy, reveals functional protein biology, captures the phenome and provides benchtop devices, enabling biopharmaceutical companies and academic institutions to identify patient immune responses at single-cell resolution.
Contact Information
Website
www.isoplexis.comCorporate Office
- 35 NorthEast Industrial Road
- Branford, CT 06405
- United States
Corporate Office
- 35 NorthEast Industrial Road
- Branford, CT 06405
- United States
IsoPlexis Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 15. Bankruptcy: Admin/Reorg | 31-Mar-2023 | Completed | Bankruptcy: Admin/Reorg | |||
| 14. Merger/Acquisition | 21-Mar-2023 | Completed | Generating Revenue | |||
| 13. IPO | 08-Oct-2021 | Completed | Generating Revenue | |||
| 12. Later Stage VC (Series D) | 11-May-2021 | Completed | Generating Revenue | |||
| 11. Mezzanine | 30-Dec-2020 | Completed | Generating Revenue | |||
| 10. Grant | 15-Jun-2020 | Completed | Generating Revenue | |||
| 9. Grant | 01-Jan-2020 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series C) | 15-Apr-2020 | Completed | Generating Revenue | |||
| 7. Grant | 01-Aug-2019 | $989K | $17.6M | Completed | Generating Revenue | |
| 6. Debt Repayment | 15-Mar-2019 | $400K | $17.6M | Completed | Generating Revenue |
IsoPlexis Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C2 | ||||||||
| Series C | ||||||||
| Series B2 | ||||||||
| Series B | ||||||||
| Series A2 | 293,180 | $0.001000 | 8% | $12.59 | $12.59 | 1x | $12.59 | 6.78% |
| Series A | 253,862 | $0.001000 | 8% | $6.5 | $6.5 | 1x | $6.5 | 5.87% |
IsoPlexis Comparisons
Industry
Financing
Details
IsoPlexis Competitors (20)
One of IsoPlexis’s 20 competitors is Biocartis, a Venture Capital-Backed company based in Mechelen, Belgium.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biocartis | Venture Capital-Backed | Mechelen, Belgium | ||||
| Rheonix | Venture Capital-Backed | Ithaca, NY | ||||
| T2 Biosystems | Formerly VC-backed | Lexington, MA | ||||
| Q-linea | Formerly VC-backed | Uppsala, Sweden | ||||
| BioGenex Laboratories | Corporation | Fremont, CA |
IsoPlexis Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
IsoPlexis Patents
IsoPlexis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024011134-A1 | Systems, devices and methods for multiplexed analysis | Inactive | 05-Jul-2022 | ||
| US-20240011088-A1 | Methods and devices for spatially resolved analysis of proteomic and genetic information | Pending | 19-Feb-2021 | ||
| WO-2022178253-A1 | Methods and devices for spatially resolved analysis of proteomic and genetic information | Inactive | 19-Feb-2021 | ||
| EP-4241086-A1 | Methods and devices for mulitplexed proteomic and genetic analysis and on-device preparation of cdna | Inactive | 03-Nov-2020 | ||
| US-20230416816-A1 | Methods and devices for mulitplexed proteomic and genetic analysis and on-device preparation of cdna | Pending | 03-Nov-2020 | C12Q1/6874 |
IsoPlexis Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
IsoPlexis Former Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ally Bridge Group | Growth/Expansion | Minority | ||
| BlackRock | Asset Manager | Minority | ||
| College Street Innovation Fund | Venture Capital | Minority | ||
| Connecticut Innovations | Venture Capital | Minority | ||
| Ironwood Capital | Growth/Expansion | Minority |
IsoPlexis ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Software & Services
Industry
Rank
Percentile
Enterprise and Infrastructure Software
Subindustry
Rank
Percentile
IsoPlexis FAQs
-
When was IsoPlexis founded?
IsoPlexis was founded in 2013.
-
Where is IsoPlexis headquartered?
IsoPlexis is headquartered in Branford, CT.
-
What is the size of IsoPlexis?
IsoPlexis has 290 total employees.
-
What industry is IsoPlexis in?
IsoPlexis’s primary industry is Diagnostic Equipment.
-
Is IsoPlexis a private or public company?
IsoPlexis is a Private company.
-
What is IsoPlexis’s current revenue?
The current revenue for IsoPlexis is .
-
How much funding has IsoPlexis raised over time?
IsoPlexis has raised $373M.
-
Who are IsoPlexis’s investors?
Ally Bridge Group, BlackRock, College Street Innovation Fund, Connecticut Innovations, and Ironwood Capital are 5 of 16 investors who have invested in IsoPlexis.
-
Who are IsoPlexis’s competitors?
Biocartis, Rheonix, T2 Biosystems, Q-linea, and BioGenex Laboratories are some of the 20 competitors of IsoPlexis.
-
When was IsoPlexis acquired?
IsoPlexis was acquired on 31-Mar-2023.
-
Who acquired IsoPlexis?
IsoPlexis was acquired by PhenomeX.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
